新生猪肝细胞输注治疗大白鼠急性肝功能衰竭的研究

本文报导以新生的猪肝细胞输注治疗D—氨基半乳糖致急性肝功能衰竭的大白鼠,并对其机理作了初步探讨。腹腔输注新生猪肝细胞能使发病大白鼠的存活率由对照组的16.22％提高到55.56％,用放射性同位素技术证明输注肝细胞能使病肝细胞的H-thymidine掺入量明显增加,病肝再生加快,从而使病鼠恢复健康。     

罗非鱼肝细胞作为环境污染生物监测指标的初步研究

应用细胞生物学技术，研究了河北白洋及江西乐安江水样对罗非鱼原代肝细胞的影响，结果表明，白洋淀府河的４个采样点（望亭、际头、大桥、王家寨）水样对罗非鱼肝细胞具有生物毒性，入淀后另２个水样（刘庄，枣林庄）则基本无影响，在乐安江所采集的３个水样中。接渡样点样品对罗非鱼肝细胞毒性最大，沽口，虎山次之。     

Differentiation of human embryonic stem cells along a hepatocyte lineage and its application in liver regeneration

Hepatocyte transplantation and bioarUficial liver （BAL） as alternatives to liver transplantation offer the possibility of effective treatment for many inherited and acquired hepatic disorders. Unfortunately, the limited availability of donated livers and the variability of their derived hepatocytes make it difficult to obtain enough viable human hepatocytes for the hepatocyte-based therapies. Embryonic stem cells （ESCs）, which could be isolated directly from the blastocyst inner cell mass, have permanent self-renewal capability and developmental pluripotency and therefore might be an ideal cell source in the treatment of hepatic discords. However, differentiation of hESCs into hepatocytes with significant numbers remains a challenge. This review updates our current understanding of differentiation of ESCs into hepatic lineage cells, their future therapeutic uses and problems in liver regeneration.     

促肝细胞生长素联合还原型谷胱甘肽治疗重度慢性乙型肝炎

目的观察促肝细胞生长素联合还原型谷胱甘肽治疗重度慢性乙型肝炎的临床疗效。方法选择60例重度慢性乙型肝炎随机分为对照组和治疗组各30例,比较治疗前后两组病人的临床症状和生化指标等方面的变化。对照组给予甘草酸二铵、香丹等抗炎保肝支持及防治并发症治疗;治疗组在此基础上加用促肝细胞生长素和还原型谷胱甘肽联合治疗。结果治疗组疗效明显优于对照组,治疗组在临床症状和生化指标改善等方面与对照组比疗效差异有显著性意义（P〈0．05）。结论两药联用有助于改善临床症状和生化指标。缩短重度慢性乙型肝炎的病程,防治疾病进展。     

中华大蟾蜍冬眠前与出眠初期肝细胞超微结构的观察

冬眠前和出眠初期的中华大蟾蜍肝细胞的超微结构有如下特点 :(1)冬眠前肝细胞堆积有大量糖元颗粒 ,而出眠初期几乎无糖元颗粒 ;(2 )冬眠前肝细胞的粗面内质网非常发达 ,而出眠初期的粗面内质网不发达 ,常呈零散膨大 ;(3)线粒体的数量 ,细胞核和胆小管的形态结构在这两个时期无明显差异 ;(4)冬眠前肝细胞可分为两种不同的类型 对上述结果的生理意义作了讨论     

脂质体转染人肝星状细胞和肝细胞条件优化

利用Lipofectamine 2000(Lipo)介导LacZ及EGFP基因转染人肝星状细胞系LX-2和人肝细胞系Chang Liver,探讨Lipo用量、质粒用量、转染时间、细胞初始接种密度及不同启动子驱动对转染效率的影响.结果显示,两种细胞均能得到高效转染,Chang Liver细胞转染效率(80%)高于LX-2细胞(60%).Lipo用量为每孔2μL,转染后6 h换液,LX-2细胞应用质粒DNA为每孔0.45μg,Chang Liver细胞应用质粒DNA为每孔0.30~0.45μg,此时转染效率最高.巨细胞病毒(CMV)启动子驱动LacZ转染效率与CMV早期增强子/鸡β肌动蛋白(CAG)启动子驱动增强型绿色荧光蛋白(EGFP)转染效率无显著差异;细胞初始接种密度对转染效率无显著影响.     

Therapeutic angiogenesis induced by human hepatocyte growth factor (HGF) gene in rat myocardial ischemia models

Coronary arteriosclerotic cardiopathy is also named myocardial ischemia, which severely threatens humanhealth. Following the economic development and change of life style in China, population blood pressure, weight index and serum cholesterol level all rise. This prophesies incidence rate of coronary arteriosclerotic cardiopathy and stroke will increase year by year. Angioplasty and surgical bypass, the primary interventional therapies for these in-dividuals, are temporally limited by the prob…     

Therapeutic angiogenesis induced by human hepatocyte growth factor gene in hindlimb ischemia of dogs

A preclinical study of treating peripheral srtery occlusive disease(PAD) was performed by using a hepatocyte growth factor(HGF) gene-expressing vector,plasmid pUDKH,in a dog model with complete ischemia of one hindlimb.After ligation of femoral artery of one hindlimb,pUDKH was transferred directly into the ischemic limb muscles.The angiogenic activity of the plasmid pUDKH was evaluated.On D 30 after injecting once of pUDKH at differ-ent doses into local muscles immediately after operation,the degree of augmentation of collateral vessel formation was significantly greater than that treated by blank vector.In addition,the blood flow rate of femoral artery in dogs treated with pUDKH was recovered on D90,while the folw rate was only 1/5 tp 1/3 in control dogs.The pulse amplitude of pUDKH-treated dogs was recovered on D90,but it was hardly detectable in most of the control dogs.The side effects of intramuscular transfection of pUDKH were also investi-gated,and no significant positive change was found.It is suggested that angiogenesis induced by HGF gene has the potential for clincal use in the treatment of peripheral arte-rial diseases.